The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat-Reference-Cited by-同舟云学术

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

Published:2017-04 Issue:4 Volume:19 Page:430-438
ISSN:1098-3600
Container-title:Genetics in Medicine
language:en
Short-container-title:Genetics in Medicine

Author:

Benjamin Elfrida R.,Della Valle Maria Cecilia,Wu Xiaoyang,Katz Evan,Pruthi Farhana,Bond Sarah,Bronfin Benjamin,Williams Hadis,Yu Julie,Bichet Daniel G.,Germain Dominique P.,Giugliani Roberto,Hughes Derralynn,Schiffmann Raphael,Wilcox William R.,Desnick Robert J.,Kirk John,Barth Jay,Barlow Carrolee,Valenzano Kenneth J.,Castelli Jeff,Lockhart David J.

Publisher

Elsevier BV

Subject

Genetics (clinical)

Link

http://www.nature.com/articles/gim2016122.pdf

Reference34 articles.

1. The genetic basis of Fabry disease;Gal,2006

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells;Atherosclerosis;2024-10

2. Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement;International Journal of Molecular Sciences;2024-09-09

3. Was ist gesichert in der Therapie von Morbus Fabry?;Die Innere Medizin;2024-08-06

4. Fabry nephropathy: a treatable cause of chronic kidney disease;Rare Disease and Orphan Drugs Journal;2024-07-11

5. Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis;Journal of Inherited Metabolic Disease;2024-07-04